[go: up one dir, main page]

MX2018006347A - Proteinas de fusion fmdv y e2 y usos de ellos. - Google Patents

Proteinas de fusion fmdv y e2 y usos de ellos.

Info

Publication number
MX2018006347A
MX2018006347A MX2018006347A MX2018006347A MX2018006347A MX 2018006347 A MX2018006347 A MX 2018006347A MX 2018006347 A MX2018006347 A MX 2018006347A MX 2018006347 A MX2018006347 A MX 2018006347A MX 2018006347 A MX2018006347 A MX 2018006347A
Authority
MX
Mexico
Prior art keywords
fmdv
antigens
fusion proteins
encompasses
vaccine
Prior art date
Application number
MX2018006347A
Other languages
English (en)
Other versions
MX382535B (es
Inventor
Bomchil Natalia
Audonnet Jean-Christophe
Reynard Frederic
Sigoillot-Claude Cecile
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of MX2018006347A publication Critical patent/MX2018006347A/es
Publication of MX382535B publication Critical patent/MX382535B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención abarca vacunas o composiciones FMDV. La vacuna composición puede ser una vacuna o composición que contiene antígenos FMDV. La invención también abarca vectores recombinantes que codifican y que expresan antígenos FMDV, epítopos o inmunógenos que se puede utilizar para proteger animales, en particular ovinos, bovinos, caprinos o porcinos, contra FMDV. La invención además abarca métodos para hacer o producir polipéptidos antigénicos o antígenos.
MX2018006347A 2015-11-23 2016-11-16 Proteinas de fusion fmdv y e2 y usos de ellos. MX382535B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259043P 2015-11-23 2015-11-23
PCT/US2016/062367 WO2017091418A1 (en) 2015-11-23 2016-11-16 Fmdv and e2 fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
MX2018006347A true MX2018006347A (es) 2019-02-20
MX382535B MX382535B (es) 2025-03-13

Family

ID=57570585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006347A MX382535B (es) 2015-11-23 2016-11-16 Proteinas de fusion fmdv y e2 y usos de ellos.

Country Status (19)

Country Link
US (2) US9913891B2 (es)
EP (2) EP3539566A1 (es)
JP (2) JP6797206B2 (es)
KR (1) KR102153303B1 (es)
CN (1) CN108367067B (es)
AR (1) AR106792A1 (es)
AU (1) AU2016361305B2 (es)
BR (1) BR112018010494A8 (es)
CA (1) CA3006078A1 (es)
DK (1) DK3380119T3 (es)
ES (1) ES2899230T3 (es)
MA (3) MA49414A (es)
MX (1) MX382535B (es)
NZ (1) NZ743236A (es)
RU (1) RU2714428C2 (es)
TW (1) TWI744260B (es)
UY (1) UY36995A (es)
WO (1) WO2017091418A1 (es)
ZA (1) ZA201803390B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX2020009720A (es) * 2018-03-19 2021-01-08 Boehringer Ingelheim Vetmedica China Co Ltd Virus recombinante capaz de expresar de manera estable proteinas objetivo.
CN109187993B (zh) * 2018-09-13 2020-06-16 中国农业科学院兰州兽医研究所 一种口蹄疫A型病毒sIgA抗体ELISA检测试剂盒及其应用
CN111233984B (zh) * 2018-11-29 2022-08-12 普莱柯生物工程股份有限公司 一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
CN110028160B (zh) * 2019-01-24 2022-04-29 暨南大学 一种功能性微藻固定化材料的制备方法及其应用
WO2020263062A1 (ko) * 2019-06-28 2020-12-30 (주)플럼라인생명과학 구제역 바이러스 백신 조성물
CN115925907B (zh) * 2022-09-19 2025-08-05 北京田园奥瑞生物科技有限公司 一种羊口蹄疫纳米抗体及其在精液保藏检测中的应用
CN119505021B (zh) * 2025-01-20 2025-04-18 内蒙古和讯生物科技有限公司 一种重复结构单元重组蛋白cpE2及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
EP0260148A3 (en) 1986-09-12 1989-06-07 Genentech, Inc. Improved recombinant expression method, vector and transformed cells
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
CA2214029A1 (en) 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
PL337583A1 (en) 1997-06-30 2000-08-28 Rhone Poulenc Rorer Sa Improved method of transferring nucleic acid to a striated muscle and connection enabling accomplishment of this method
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
UA84024C2 (ru) 2003-07-24 2008-09-10 Мериал Лимитед Новые вакцинные композиции, которые содержат эмульсию типа "масло в воде"
US7527960B2 (en) 2004-06-25 2009-05-05 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
EP2316480A1 (en) * 2006-03-17 2011-05-04 Indian Immunologicals Ltd Chimeric tymovirus-like particles
CN101293098A (zh) * 2007-04-28 2008-10-29 北京迪威华宇生物技术有限公司 一种重组牛o型口蹄疫病毒融合蛋白疫苗
SG179037A1 (en) 2009-09-10 2012-04-27 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
EP2545067B1 (en) * 2010-03-12 2016-11-30 Merial, Inc. Bluetongue virus recombinant vaccines and uses thereof
RU2467014C2 (ru) * 2010-12-06 2012-11-20 Учреждение Российской академии наук Центр "Боинженерия" РАН Полиэпитопный белок, нуклеотидная последовательность, кодирующая полиэпитопный белок, плазмида с последовательностью, кодирующей полиэпитопный белок, и препарат полиэпитопного белка для индукции иммунного ответа против вируса ящура
KR20150084993A (ko) * 2012-11-16 2015-07-22 유나이티드 바이오메디칼 인크. 구제역 (fmd)에 대한 합성 펩티드-기재 응급 백신
EP2928491B1 (en) * 2012-12-05 2018-11-21 TheVax Genetics Vaccine Co., Ltd. Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
CN103305542B (zh) * 2013-06-25 2015-03-11 江苏省农业科学院 一种重组噬菌体双表达载体及应用
US10744199B2 (en) * 2013-10-11 2020-08-18 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Epstein-Barr virus vaccines
CN103933581A (zh) * 2014-05-04 2014-07-23 贵州大学 一种基于csf-fmd二联基因工程疫苗的制备方法
AP2017009834A0 (en) 2014-09-23 2017-03-31 Merial Inc Fmdv recombinant vaccines and uses thereof

Also Published As

Publication number Publication date
US20180169216A1 (en) 2018-06-21
ZA201803390B (en) 2019-03-27
US10363300B2 (en) 2019-07-30
BR112018010494A2 (pt) 2018-11-13
US20170143819A1 (en) 2017-05-25
RU2018122755A (ru) 2019-12-26
KR20180084995A (ko) 2018-07-25
AU2016361305A1 (en) 2018-06-28
WO2017091418A1 (en) 2017-06-01
EP3539566A1 (en) 2019-09-18
CN108367067A (zh) 2018-08-03
TW201726708A (zh) 2017-08-01
CN108367067B (zh) 2022-05-03
HK1258695A1 (en) 2019-11-15
EP3380119A1 (en) 2018-10-03
MA42640B1 (fr) 2021-06-30
RU2018122755A3 (es) 2019-12-26
KR102153303B1 (ko) 2020-09-09
DK3380119T3 (da) 2021-11-15
MA49414A (fr) 2020-04-22
JP2019500409A (ja) 2019-01-10
NZ743236A (en) 2019-12-20
JP2020203890A (ja) 2020-12-24
EP3380119B1 (en) 2021-08-25
TWI744260B (zh) 2021-11-01
MA42640A1 (fr) 2019-05-31
MA43310A (fr) 2021-04-28
US9913891B2 (en) 2018-03-13
BR112018010494A8 (pt) 2019-02-26
RU2714428C2 (ru) 2020-02-14
CA3006078A1 (en) 2017-06-01
ES2899230T3 (es) 2022-03-10
MX382535B (es) 2025-03-13
UY36995A (es) 2017-06-30
AR106792A1 (es) 2018-02-21
AU2016361305B2 (en) 2020-02-06
JP6797206B2 (ja) 2020-12-09

Similar Documents

Publication Publication Date Title
MX2017003712A (es) Vacunas recombinantes contra fmdv y sus usos.
MX2018006347A (es) Proteinas de fusion fmdv y e2 y usos de ellos.
MX391908B (es) Vacunas de fmdv vectorizadas con adenovirus recombinantes y usos de las mismas.
BR112012023046A2 (pt) vacinas de vírus de febre aftosa recombinantes e seus respectivos usos
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
MX2022000222A (es) Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso.
MX373277B (es) Polipeptidos fhbp meningococicos modificados.
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
NZ734938A (en) Leptospira immunoprotective proteins and methods of identification and use thereof
MX2016017094A (es) Composicion inmunógena de clostridium difficile.
UY36328A (es) Vacunas de fmdv recombinante y usos de las mismas
PH12018500372B1 (en) Fcv recombinant vaccines and uses thereof
MX2010008170A (es) Vacunas para influenza canina.
AR095501A1 (es) Vacunas rsv